{
    "clinical_study": {
        "@rank": "119306", 
        "arm_group": [
            {
                "arm_group_label": "Normal Saline Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes."
            }, 
            {
                "arm_group_label": "Allogeneic Mesenchymal Precursor Cells", 
                "arm_group_type": "Active Comparator", 
                "description": "Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "Study is a double-blind, randomized, placebo controlled, dose escalating study.  The primary\n      objective of this study is to evaluate the safety, tolerability and feasibility of a single\n      intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at\n      12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA)\n      who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and\n      who have had an incomplete response to at least one TNF-alpha inhibitor."
        }, 
        "brief_title": "A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor", 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and Females ages 18-80 years old\n\n          -  Active rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification\n             criteria for the diagnosis of RA.\n\n          -  Must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide\n             (anti-CCP3) but without extra-articular disease or functional limitation\n\n          -  Patient with active RA defined as:\n\n               -  4 tender joints (TJC) count (28 joint count) at screening and\n\n               -  4 swollen joints (SJC) count (28 joint count) at screening\n\n          -  ESR \u2265 28 mm/hr OR hsCRP greater than ULN\n\n          -  Patient has been taking MTX for at least 6 months with dose and route of\n             administration stable for at least 8 weeks prior to screening\n\n          -  Patient has had an inadequate response to at least one TNF\u03b1 inhibitor with last dose\n             at least 6 weeks prior to screening\n\n          -  Use of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is\n             permitted but must be stable for at least 3 months prior to screening\n\n        Exclusion Criteria:\n\n          -  Pregnant women or women who are breastfeeding.\n\n          -  Other investigational therapy received within 8 weeks or five half-lives (whichever\n             is longer) prior to Screening (except as in exclusion #13).\n\n          -  Known or suspected alcohol or drug abuse within three years preceding Screening.\n\n          -  Autoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed\n             connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis)\n\n          -  History of or current inflammatory joint disease other than RA (such as tophaceous\n             gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other\n             spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis\n             are excluded.\n\n          -  Bedridden or confined to a wheelchair or patients with > 3 arthroplasties due to RA.\n\n          -  History of diagnosed and/or treated malignancy (except for treated basal cell or\n             squamous cell carcinoma of the skin or cervical carcinoma in situ with no evidence of\n             recurrence).\n\n          -  Surgical procedures planned to occur during the trial (these patients may be\n             rescreened following completion of and recovery from the surgical procedure).\n\n          -  Use of TNF\u03b1 inhibitor for treatment of RA at time of screening or within the 6 weeks\n             prior to screening.\n\n          -  Prior use of more than two biologics in addition to TNF\u03b1 inhibitors for treatment of\n             RA."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01851070", 
            "org_study_id": "MSB-RA001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Normal Saline Placebo", 
                "intervention_name": "Allogeneic Mesenchymal Precursor Cells", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Allogeneic Mesenchymal Precursor Cells", 
                "intervention_name": "Normal Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "abolt@pinnacletrials.com", 
                    "last_name": "April Bolt", 
                    "phone": "256-236-0055", 
                    "phone_ext": "111"
                }, 
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36207"
                    }, 
                    "name": "Pinnacle Research Group"
                }, 
                "investigator": {
                    "last_name": "Vishala Chindalore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "research3@arthrocarepc.com", 
                    "last_name": "Chanel Tate", 
                    "phone": "480-245-7663"
                }, 
                "facility": {
                    "address": {
                        "city": "Gilbert", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85234"
                    }, 
                    "name": "Arthrocare Arthritis Care and Research PC"
                }, 
                "investigator": {
                    "last_name": "Michael Fairfax, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nbarroso@mednet.ucla.edu", 
                    "last_name": "Nashla Barroso", 
                    "phone": "310-825-9682"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90025"
                    }, 
                    "name": "UCLA"
                }, 
                "investigator": {
                    "last_name": "Daniel Furst, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "calvarez@irclinicaltrials.com", 
                    "last_name": "Carlos Alvarez", 
                    "phone": "909-296-8701"
                }, 
                "facility": {
                    "address": {
                        "city": "Upland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91786"
                    }, 
                    "name": "Inland Rheumatology Clinical Trials Incorporated"
                }, 
                "investigator": {
                    "last_name": "Antony Hou, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kathrynvallancecrc@yahoo.com", 
                    "last_name": "Kathryn Vallance", 
                    "phone": "352-861-6931"
                }, 
                "facility": {
                    "address": {
                        "city": "Ocala", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34474"
                    }, 
                    "name": "Ocala Rheumatology Research Center"
                }, 
                "investigator": {
                    "last_name": "Stephen Bookbinder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sjones@arthritiscenter.org", 
                    "last_name": "Shonte Jones", 
                    "phone": "727-789-2784", 
                    "phone_ext": "23"
                }, 
                "facility": {
                    "address": {
                        "city": "Palm Harbor", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34684"
                    }, 
                    "name": "Arthritis Center"
                }, 
                "investigator": {
                    "last_name": "Mitchell Lowenstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tsmalls.sarc@comcast.net", 
                    "last_name": "Tasha Smalls", 
                    "phone": "941-366-1244"
                }, 
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34239"
                    }, 
                    "name": "Sarasota Arthritis Research Center"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Kaine, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mctowns@jhmi.edu", 
                    "last_name": "Marilyn Towns", 
                    "phone": "410-550-0579"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21224"
                    }, 
                    "name": "JHU Arthritis Center Baltimore"
                }, 
                "investigator": {
                    "last_name": "Clifton Bingham, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mstrieter@arthritistreatmentcenter.com", 
                    "last_name": "Mary L Strieter", 
                    "phone": "301-624-1167"
                }, 
                "facility": {
                    "address": {
                        "city": "Frederick", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21702"
                    }, 
                    "name": "Arthritis Treatment Center"
                }, 
                "investigator": {
                    "last_name": "Nathan Wei, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marcia.kirkpatrick@reliantmedicalgroup.org", 
                    "last_name": "Marcia Kirkpatrick", 
                    "phone": "508-556-5429"
                }, 
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01609"
                    }, 
                    "name": "Reliant Medical Group"
                }, 
                "investigator": {
                    "last_name": "John Hosey, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hanf.heidi@mayo.edu", 
                    "last_name": "Heidi Hanf", 
                    "phone": "507-266-4175"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Eric L Matteson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "smartmanju@hotmail.com", 
                    "last_name": "Manju Gupta", 
                    "phone": "901-681-9670"
                }, 
                "facility": {
                    "address": {
                        "city": "Fair Lawn", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07410"
                    }, 
                    "name": "Office of Ramesh C. Gupta, MD"
                }, 
                "investigator": {
                    "last_name": "Ramesh Gupta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "julianagaeva@boxarthritis.com", 
                    "last_name": "Julia Nagaeva", 
                    "phone": "704-541-9092", 
                    "phone_ext": "212"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28210"
                    }, 
                    "name": "DJL Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Emily Box, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cbowling@healthresearchok.com", 
                    "last_name": "Crista Bowling", 
                    "phone": "405-702-6770"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73102"
                    }, 
                    "name": "Health Research of Oklahoma"
                }, 
                "investigator": {
                    "last_name": "Christine Codding, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mcbridedl@upmc.edu", 
                    "last_name": "Dawn McBride", 
                    "phone": "412-648-9413"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15261"
                    }, 
                    "name": "University of Pittsburgh"
                }, 
                "investigator": {
                    "last_name": "Larry Moreland, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tlawrence@arthritisclinic.org", 
                    "last_name": "Trina Lawrence", 
                    "phone": "731-951-0249"
                }, 
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38305"
                    }, 
                    "name": "West Tennessee Research Institute"
                }, 
                "investigator": {
                    "last_name": "Jacob Aelion, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "robmaces@accurateclinicalresearch.com", 
                    "last_name": "Ronald Obmaces", 
                    "phone": "281-481-8557"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77034"
                    }, 
                    "name": "Accurate Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Philip Waller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 6 months and who have had an incomplete response to at least one course of a TNF\u03b1 inhibitor.\nOverall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs, pulmonary function tests and Chest x-ray.", 
            "measure": "Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks post IV Infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01851070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Efficacy will be assessed according to the following criteria:\nACR20/50/70\nMean changes from baseline in DAS28 (hsCRP)\nMean changes from baseline in all components of the ACR core response criteria:  Swollen joint count, Tender joint count, Investigator global assessment of disease activity (VAS), Patient global assessment of disease activity (VAS), Patient reported pain (VAS), Health Assessment Questionnaire (HAQ-DI), ESR or hsCRP\nRemissions (as defined in the 2011 Joint Statement of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)", 
                "measure": "Demonstration of efficacy of allogeneic MPCs compared to placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active rheumatoid arthritis", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post IV infusion with MPCs"
            }, 
            {
                "description": "Safety will be assessed according to the following:\nAdverse events/serious adverse events (\"primary endpoint\")\nVital signs\nPhysical examination\nClinical laboratory tests\nElectrocardiogram\nPulmonary function tests\nChest x-ray (CXR)\nEfficacy will be assessed according to the following:\nACR 20/50/70\nDAS28 (mean changes from baseline as measured by using hsCRP)\nMean changes from baseline in all components of the ACR core response criteria\nRemissions (as defined in the 2011 Joint Statement of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)\nJoint erosion of hands and wrists assessed via x-ray\nPatient-reported outcomes\nSF36v2\nHAQ_DI", 
                "measure": "Long-term evaluation of safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA who have received methotrexate +/- other DMARDs for at least 6 months and who have had an incomplete response to at least one TNF-alpha inhi", 
                "safety_issue": "No", 
                "time_frame": "78 weeks post IV Infusion"
            }
        ], 
        "source": "Mesoblast, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mesoblast, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}